Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Targets |
IC50: 2.4 μM (CDC25A), 3.9 μM (CDC25B2), 6.3 μM (CDC25B3), 5.4 μM (CDC25C), 4.6 μM (CDC25C-cat)[1].
|
---|---|
ln Vitro |
BN82002 is tested in vitro on a variety of human tumor cell lines to determine its impact on cell growth. For the control, menadione is utilized, which has been shown to impede the growth of cells. BN82002 and menadione both exhibit concentration-dependent sensitivity in the low micromolar range in all of the tested cell lines. The cell line with the highest sensitivity, MIA PaCa-2, is from pancreatic cancer; its IC50 is 7.2 μM, while HT-29, from colon cancer, has a lower sensitivity of 32.6 ΔM. Comparable to the menadione (5–15 μM) range of action is reported. The results also indicate that 50 μM BN82002 completely suppresses cell division; the distribution of the cell cycle is only slightly altered, with a small reduction in S phase and an increase in cells with both G1 and G2 DNA content, indicating that the treated cells are arrested at different phases of the cell cycle[1].
|
References |
[1]. Brezak MC, et al. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res. 2004 May 1;64(9):3320-5.
|
Molecular Formula |
C19H26CLN3O4
|
---|---|
Molecular Weight |
395.88
|
CAS # |
1049740-43-3
|
Related CAS # |
BN82002;396073-89-5
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
C(C1C=C(N(C)C)C=C(OC)C=1O)N(C)CCC1C=CC(N(=O)=O)=CC=1.Cl
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 220 mg/mL (555.72 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5.5 mg/mL (13.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 55.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5.5 mg/mL (13.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 55.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 5.5 mg/mL (13.89 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5260 mL | 12.6301 mL | 25.2602 mL | |
5 mM | 0.5052 mL | 2.5260 mL | 5.0520 mL | |
10 mM | 0.2526 mL | 1.2630 mL | 2.5260 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.